Raphael J Landovitz1, Deborah Donnell1, Meredith E Clement1, Brett Hanscom1, Leslie Cottle1, Lara Coelho1, Robinson Cabello1, Suwat Chariyalertsak1, Eileen F Dunne1, Ian Frank1, Jorge A Gallardo-Cartagena1, Aditya H Gaur1, Pedro Gonzales1, Ha V Tran1, Juan C Hinojosa1, Esper G Kallas1, Colleen F Kelley1, Marcelo H Losso1, J Valdez Madruga1, Keren Middelkoop1, Nittaya Phanuphak1, Breno Santos1, Omar Sued1, Javier Valencia Huamaní1, Edgar T Overton1, Shobha Swaminathan1, Carlos Del Rio1, Roy M Gulick1, Paul Richardson1, Philip Sullivan1, Estelle Piwowar-Manning1, Mark Marzinke1, Craig Hendrix1, Maoji Li1, Zhe Wang1, Jeanne Marrazzo1, Eric Daar1, Aida Asmelash1, Todd T Brown1, Peter Anderson1, Susan H Eshleman1, Marcus Bryan1, Cheryl Blanchette1, Jonathan Lucas1, Christina Psaros1, Steven Safren1, Jeremy Sugarman1, Hyman Scott1, Joseph J Eron1, Sheldon D Fields1, Nirupama D Sista1, Kailazarid Gomez-Feliciano1, Andrea Jennings1, Ryan M Kofron1, Timothy H Holtz1, Katherine Shin1, James F Rooney1, Kimberly Y Smith1, William Spreen1, David Margolis1, Alex Rinehart1, Adeola Adeyeye1, Myron S Cohen1, Marybeth McCauley1, Beatriz Grinsztejn1. 1. From the Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles (R.J.L., R.M.K.), the Lundquist Institute at Harbor-UCLA Medical Center, Torrance (E.D.), the San Francisco Department of Public Health, San Francisco (H.S.), and Gilead Sciences, Foster City (J.F.R.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (D.D., B.H., L. Cottle, M.L., Z.W.); the Louisiana State University Health Sciences Center, New Orleans (M.E.C.); Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro (L. Coelho, B.G.), University of São Paulo (E.G.K.), and Centro de Referência e Treinamento DST-AIDS-SP (J.V.M.), São Paulo, and Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Via Libre (R.C.), Universidad Nacional Mayor de San Marcos (J.A.G.-C.), and Asociacion Civil Impacta Salud y Educacion (P.G., J.V.H.), Lima, and Asociacion Civil Selva Amazonica, Iquitos (J.C.H.) - all in Peru; the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai (S.C.), and the Institute of HIV Research and Innovation, Bangkok (N.P.) - both in Thailand; the Division of HIV-AIDS Prevention, Centers for Disease Control and Prevention (E.F.D.), the School of Medicine (C.F.K., C.R.), and Rollins School of Public Health (C.R.), Emory University - both in Atlanta; the Perelman School of Medicine, University of Pennsylvania, Philadelphia (I.F.), and Pennsylvania State University, State College (S.D.F.) - both in Pennsylvania; St. Jude Children's Research Hospital, Memphis, TN (A.H.G.); University of North Carolina at Chapel Hill, Chapel Hill (H.V.T., J.J.E., M.S.C.), FHI 360, Durham (A. Asmelash, M.B., C.B., J.L., N.D.S., K.G.-F., A.J., M.M.), and ViiV Healthcare, Research Triangle (K.Y.S., W.S., D.M., A.R.) - all in North Carolina; Hospital General de Agudos José María Ramos Mejia (M.H.L.) and Fundación Huésped (O.S.) - both in Buenos Aires; the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (K.M.); University of Alabama at Birmingham, Birmingham (E.T.O., J.M.); Rutgers New Jersey Medical School, Newark (S. Swaminathan); Weill Cornell Medicine, New York (R.M.G.); Johns Hopkins University, Baltimore (P.R., P.S., E.P.-M., M.M., C.H., T.T.B., S.H.E., J.S.); University of Colorado Anschutz Medical Campus, Aurora (P.A.); Massachusetts General Hospital, Boston (C.P.); University of Miami, Coral Gables, FL (S. Safren); the Office of AIDS Research (T.H.H.) and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD (K.S., A. Adeyeye).
Abstract
BACKGROUND: Safe and effective long-acting injectable agents for preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options for preventing HIV infection. METHODS: We conducted a randomized, double-blind, double-dummy, noninferiority trial to compare long-acting injectable cabotegravir (CAB-LA, an integrase strand-transfer inhibitor [INSTI]) at a dose of 600 mg, given intramuscularly every 8 weeks, with daily oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) for the prevention of HIV infection in at-risk cisgender men who have sex with men (MSM) and in at-risk transgender women who have sex with men. Participants were randomly assigned (1:1) to receive one of the two regimens and were followed for 153 weeks. HIV testing and safety evaluations were performed. The primary end point was incident HIV infection. RESULTS: The intention-to-treat population included 4566 participants who underwent randomization; 570 (12.5%) identified as transgender women, and the median age was 26 years (interquartile range, 22 to 32). The trial was stopped early for efficacy on review of the results of the first preplanned interim end-point analysis. Among 1698 participants from the United States, 845 (49.8%) identified as Black. Incident HIV infection occurred in 52 participants: 13 in the cabotegravir group (incidence, 0.41 per 100 person-years) and 39 in the TDF-FTC group (incidence, 1.22 per 100 person-years) (hazard ratio, 0.34; 95% confidence interval, 0.18 to 0.62). The effect was consistent across prespecified subgroups. Injection-site reactions were reported in 81.4% of the participants in the cabotegravir group and in 31.3% of those in the TDF-FTC group. In the participants in whom HIV infection was diagnosed after exposure to CAB-LA, INSTI resistance and delays in the detection of HIV infection were noted. No safety concerns were identified. CONCLUSIONS: CAB-LA was superior to daily oral TDF-FTC in preventing HIV infection among MSM and transgender women. Strategies are needed to prevent INSTI resistance in cases of CAB-LA PrEP failure. (Funded by the National Institute of Allergy and Infectious Diseases and others; HPTN 083 ClinicalTrials.gov number, NCT02720094.).
BACKGROUND: Safe and effective long-acting injectable agents for preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options for preventing HIV infection. METHODS: We conducted a randomized, double-blind, double-dummy, noninferiority trial to compare long-acting injectable cabotegravir (CAB-LA, an integrase strand-transfer inhibitor [INSTI]) at a dose of 600 mg, given intramuscularly every 8 weeks, with daily oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) for the prevention of HIV infection in at-risk cisgender men who have sex with men (MSM) and in at-risk transgender women who have sex with men. Participants were randomly assigned (1:1) to receive one of the two regimens and were followed for 153 weeks. HIV testing and safety evaluations were performed. The primary end point was incident HIV infection. RESULTS: The intention-to-treat population included 4566 participants who underwent randomization; 570 (12.5%) identified as transgender women, and the median age was 26 years (interquartile range, 22 to 32). The trial was stopped early for efficacy on review of the results of the first preplanned interim end-point analysis. Among 1698 participants from the United States, 845 (49.8%) identified as Black. Incident HIV infection occurred in 52 participants: 13 in the cabotegravir group (incidence, 0.41 per 100 person-years) and 39 in the TDF-FTC group (incidence, 1.22 per 100 person-years) (hazard ratio, 0.34; 95% confidence interval, 0.18 to 0.62). The effect was consistent across prespecified subgroups. Injection-site reactions were reported in 81.4% of the participants in the cabotegravir group and in 31.3% of those in the TDF-FTC group. In the participants in whom HIV infection was diagnosed after exposure to CAB-LA, INSTI resistance and delays in the detection of HIV infection were noted. No safety concerns were identified. CONCLUSIONS: CAB-LA was superior to daily oral TDF-FTC in preventing HIV infection among MSM and transgender women. Strategies are needed to prevent INSTI resistance in cases of CAB-LA PrEP failure. (Funded by the National Institute of Allergy and Infectious Diseases and others; HPTN 083 ClinicalTrials.gov number, NCT02720094.).
Authors: Kenneth H Mayer; Jean-Michel Molina; Melanie A Thompson; Peter L Anderson; Karam C Mounzer; Joss J De Wet; Edwin DeJesus; Heiko Jessen; Robert M Grant; Peter J Ruane; Pamela Wong; Ramin Ebrahimi; Lijie Zhong; Anita Mathias; Christian Callebaut; Sean E Collins; Moupali Das; Scott McCallister; Diana M Brainard; Cynthia Brinson; Amanda Clarke; Pep Coll; Frank A Post; C Bradley Hare Journal: Lancet Date: 2020-07-25 Impact factor: 79.321
Authors: Robert M Grant; Peter L Anderson; Vanessa McMahan; Albert Liu; K Rivet Amico; Megha Mehrotra; Sybil Hosek; Carlos Mosquera; Martin Casapia; Orlando Montoya; Susan Buchbinder; Valdilea G Veloso; Kenneth Mayer; Suwat Chariyalertsak; Linda-Gail Bekker; Esper G Kallas; Mauro Schechter; Juan Guanira; Lane Bushman; David N Burns; James F Rooney; David V Glidden Journal: Lancet Infect Dis Date: 2014-07-22 Impact factor: 25.071
Authors: Raphael J Landovitz; Sue Li; Joseph J Eron; Beatriz Grinsztejn; Halima Dawood; Albert Y Liu; Manya Magnus; Mina C Hosseinipour; Ravindre Panchia; Leslie Cottle; Gordon Chau; Paul Richardson; Mark A Marzinke; Susan H Eshleman; Ryan Kofron; Adeola Adeyeye; David Burns; Alex R Rinehart; David Margolis; Myron S Cohen; Marybeth McCauley; Craig W Hendrix Journal: Lancet HIV Date: 2020-06-01 Impact factor: 12.767
Authors: Kassem Bourgi; Peter F Rebeiro; Megan Turner; Jessica L Castilho; Todd Hulgan; Stephen P Raffanti; John R Koethe; Timothy R Sterling Journal: Clin Infect Dis Date: 2020-03-17 Impact factor: 9.079
Authors: Pamela M Murnane; Connie Celum; Nelly Mugo; James D Campbell; Deborah Donnell; Elizabeth Bukusi; Andrew Mujugira; Jordan Tappero; Erin M Kahle; Katherine K Thomas; Jared M Baeten Journal: AIDS Date: 2013-08-24 Impact factor: 4.177
Authors: Jean-Michel Molina; Catherine Capitant; Bruno Spire; Gilles Pialoux; Laurent Cotte; Isabelle Charreau; Cecile Tremblay; Jean-Marie Le Gall; Eric Cua; Armelle Pasquet; François Raffi; Claire Pintado; Christian Chidiac; Julie Chas; Pierre Charbonneau; Constance Delaugerre; Marie Suzan-Monti; Benedicte Loze; Julien Fonsart; Gilles Peytavin; Antoine Cheret; Julie Timsit; Gabriel Girard; Nicolas Lorente; Marie Préau; James F Rooney; Mark A Wainberg; David Thompson; Willy Rozenbaum; Veronique Doré; Lucie Marchand; Marie-Christine Simon; Nicolas Etien; Jean-Pierre Aboulker; Laurence Meyer; Jean-François Delfraissy Journal: N Engl J Med Date: 2015-12-01 Impact factor: 91.245
Authors: Charles Dobard; Natalia Makarova; Kenji Nishiura; Chuong Dinh; Angela Holder; Mara Sterling; Jonathan Lipscomb; James Mitchell; Frank Deyounks; David Garber; George Khalil; William Spreen; Walid Heneine; J Gerardo García-Lerma Journal: J Infect Dis Date: 2020-07-06 Impact factor: 5.226
Authors: Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Raphael J Landovitz; Sue Li; Beatriz Grinsztejn; Halima Dawood; Albert Y Liu; Manya Magnus; Mina C Hosseinipour; Ravindre Panchia; Leslie Cottle; Gordon Chau; Paul Richardson; Mark A Marzinke; Craig W Hendrix; Susan H Eshleman; Yinfeng Zhang; Elizabeth Tolley; Jeremy Sugarman; Ryan Kofron; Adeola Adeyeye; David Burns; Alex R Rinehart; David Margolis; William R Spreen; Myron S Cohen; Marybeth McCauley; Joseph J Eron Journal: PLoS Med Date: 2018-11-08 Impact factor: 11.069
Authors: Morgan M Philbin; Sadie Bergen; Carrigan Parish; Deanna Kerrigan; Elizabeth N Kinnard; Sarah Reed; Mardge H Cohen; Oluwakemi Sosanya; Anandi N Sheth; Adaora A Adimora; Jennifer Cocohoba; Lakshmi Goparaju; Elizabeth T Golub; Michael Vaughn; José I Gutierrez; Margaret A Fischl; Maria Alcaide; Lisa R Metsch Journal: AIDS Behav Date: 2021-10-14
Authors: Amir M Mohareb; Joseph Larmarange; Arthur Y Kim; Patrick A Coffie; Menan Gérard Kouamé; Anders Boyd; Kenneth A Freedberg; Emily P Hyle Journal: Lancet HIV Date: 2022-07-08 Impact factor: 16.070
Authors: LaRon E Nelson; Donte T Boyd; Geetha Beauchamp; Lynda Emel; Leo Wilton; Darren Whitfield; S Raquel Ramos; Wale Ajiboye; Mandy J Hill; Donaldson F Conserve; Portia Thomas; Lisa Hightow-Weidman; Steve Shoptaw; Manya Magnus; Kenneth H Mayer; Estelle Piwowar-Manning; Sheldon D Fields; Darrell P Wheeler Journal: J Urban Health Date: 2022-08-08 Impact factor: 5.801
Authors: William C Goedel; Brooke G Rogers; Yu Li; Amy S Nunn; Rupa R Patel; Brandon D L Marshall; Leandro A Mena; Lori M Ward; J Benjamin Brock; Siena Napoleon; Alexandra Zanowick-Marr; Kate Curoe; Ashley Underwood; Catrell J Johnson; Khadijra R Lockwood; Philip A Chan Journal: J Acquir Immune Defic Syndr Date: 2022-10-01 Impact factor: 3.771
Authors: Vicente Soriano; Ana Treviño; Carmen de Mendoza; Víctor Moreno-Torres; Ilduara Pintos; Pablo Barreiro; Octavio Corral Journal: Infez Med Date: 2022-09-01